Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 67 | 12 | 53 |
| Samples | 66 | 12 | 52 |
| Peptides | 51 | 9 | 42 |
Function
CRH · Corticotropin releasing hormone
This gene encodes a member of the corticotropin-releasing factor family. The encoded preproprotein is proteolytically processed to generate the mature neuropeptide hormone. In response to stress, this hormone is secreted by the paraventricular nucleus (PVN) of the hypothalamus, binds to corticotropin releasing hormone receptors and stimulates the release of adrenocorticotropic hormone from the pituitary gland. Marked reduction in this protein has been observed in association with Alzheimer's disease. Autosomal recessive hypothalamic corticotropin deficiency has multiple and potentially fatal metabolic consequences including hypoglycemia and hepatitis. In addition to production in the hypothalamus, this protein is also synthesized in peripheral tissues, such as T lymphocytes, and is highly expressed in the placenta. In the placenta it is a marker that determines the length of gestation and the timing of parturition and delivery. A rapid increase in circulating levels of the hormone occurs at the onset of parturition, suggesting that, in addition to its metabolic functions, this protein may act as a trigger for parturition. [provided by RefSeq, Nov 2015].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000276571 | P06850 | 67 | 51 |
Gene Properties
Recurrent Mutations
All 51 amino-acid changes on canonical ENST00000276571 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CRH · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CRH – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chordoma | 1/7 14% | 0/13 0% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Neuroendocrine Tumour | 4/154 3% | 0/577 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Melanoma | 0/210 0% | 7/1899 0% |
| Endometrial Carcinoma | 1/42 2% | 1/612 0% |
| Other Solid Cancers | 2/94 2% | 3/1515 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Gastric Carcinoma | 0/74 0% | 5/1809 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 4/1390 0% |
| Colorectal Carcinoma | 0/143 0% | 8/3239 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Ovarian Carcinoma | 2/109 2% | 0/998 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Breast Carcinoma | 0/144 0% | 5/3264 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| Head and Neck Carcinoma | 0/85 0% | 1/1574 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 1/2550 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 0/2640 0% |
Mutation Distribution
Where CRH is mutated · all tissues, split by cell line vs tissue
How many mutations in CRH were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 20 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 67 mutations in CRH
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|